Company intelligence / Profile preview

Beijing Shengshi Liangfang Pharmaceutical Technology

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Beijing Shengshi Liangfang Pharmaceutical Technology is a Chinese biotechnology company focused on the research and development of innovative small molecule drugs for metabolic diseases. The company's primary focus is on developing treatments for type 2 diabetes and obesity, with a pipeline featuring GLP-1 receptor agonists and DPP-4 inhibitors. Their lead candidate, SSLF-008, is an oral small molecule GLP-1 receptor agonist currently in clinical development. The company aims to provide more accessible and effective oral alternatives to injectable metabolic therapies.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

Quyu Zhixue Granules

Unknown

Beyond the preview

Go deeper on Beijing Shengshi Liangfang Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Shengshi Liangfang Pharmaceutical Technology.

Explore the full profile